Scholar Rock Holding Corporation develops biologic therapies for spinal muscular atrophy and other rare, severe, and debilitating neuromuscular diseases through its myostatin biology platform. Its principal program, apitegromab, is an anti-myostatin therapy being developed for children and adults with SMA, and its pipeline also includes subcutaneous apitegromab and SRK-439.
Recurring company updates include FDA regulatory activity for apitegromab, manufacturing and fill-finish matters tied to the program, quarterly financial results, cash and financing activity such as debt and at-the-market equity programs, and Nasdaq inducement equity grants for new employees. Scholar Rock also reports investor-conference participation and pipeline commentary related to anti-myostatin biology.
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company developing apitegromab for spinal muscular atrophy (SMA) and other neuromuscular diseases, will host a conference call to discuss Q2 2025 financial results on August 6, 2025, at 8:00am ET.
Investors can access the call by registering online or dialing 800-715-9871 (domestic) or 646-307-1963 (international) with conference ID 3205013. A webcast replay will be available for approximately 90 days on the company's investor relations website.
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company developing apitegromab for spinal muscular atrophy (SMA), has granted inducement equity awards to 6 new employees. The awards include 128,057 stock options at an exercise price of $38.59 and 96,043 restricted stock units.
The awards are part of the Company's 2022 Inducement Equity Plan, designed for new hires. The stock options will vest 25% after one year, with remaining 75% vesting quarterly over three years. Restricted stock units will vest in four equal annual installments, subject to continued employment.
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company specializing in developing apitegromab for spinal muscular atrophy (SMA) and other neuromuscular diseases, announced its participation in the upcoming Jefferies Global Healthcare Conference. CEO David L. Hallal and the management team will engage in a fireside chat on June 4 at 3:45 p.m. ET in New York City. The presentation will be accessible via live webcast through Scholar Rock's Investors & Media website section, with replay availability for approximately 90 days.
Scholar Rock (SRRK), a late-stage biopharmaceutical company focused on developing apitegromab for spinal muscular atrophy (SMA), has granted inducement equity awards to 14 new employees. The awards include 60,400 shares in stock options with an exercise price of $32.46 and 45,300 shares in restricted stock units.
The stock options will vest 25% after one year from each employee's start date, with the remaining 75% vesting in 12 quarterly installments. The restricted stock units will vest in four equal annual installments. These awards were granted under the Company's 2022 Inducement Equity Plan, specifically designed for new hires as per Nasdaq Listing Rule 5635(c)(4).